DeepMed Research

University of Minnesota Masonic Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Vegetable Intake Effect on Heterocyclic Amine Metabolism

Not Applicable

Terminated

Conditions: Colon Cancer

Interventions: Other: grilled hamburger (7 oz) with steamed broccoli and Brussels sprouts (3g/kg body weight combined)
Other: grilled hamburger (7 oz) with no vegetables
Other: grilled hamburger (7 oz) with steamed parsnips, fresh parsley, and celery sticks (3g/kg body weight combined)
Other: grilled hamburger (7 oz) with steamed broccoli, Brussels sprouts, and parsnips plus fresh parsley and celery sticks (6g/kg body weight combined).

First Posted Date: 2021-05-12

Last Posted Date: 2023-04-19

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 25

Registration Number: NCT04882423

Locations: 🇺🇸
University of Minnesota, Saint Paul, Minnesota, United States

Study of Periodontitis and Blood Stream Infection in AML Patients Receiving Chemotherapy

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Other: Planned Chemotherapy

First Posted Date: 2021-04-26

Last Posted Date: 2022-04-11

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 3

Registration Number: NCT04858594

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Study of E7777 Prior to Kymriah for R/R DLBCL

Phase 1

Recruiting

Conditions: DLBCL
Diffuse Large B Cell Lymphoma
High-grade B-cell Lymphoma
DLBCL Arising From Follicular Lymphoma

Interventions: Drug: E7777

First Posted Date: 2021-04-22

Last Posted Date: 2025-01-09

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 30

Registration Number: NCT04855253

Locations: 🇺🇸
University of Minnesota, Masonic Cancer Center, Minneapolis, Minnesota, United States

Impact of Low Nicotine Cigarette Messaging on Perceptions and Cigarette Choices

Early Phase 1

Completed

Conditions: Smoking
Cigarette

Interventions: Drug: Low Nicotine Content Cigarettes
Other: Control message
Other: Test message

First Posted Date: 2021-02-05

Last Posted Date: 2024-02-26

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 64

Registration Number: NCT04740008

Locations: 🇺🇸
University of Minnesota, Tobacco Research Program, 717 Delaware St., SE, Minneapolis, Minnesota, United States

FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
Myeloid Leukemia
Monocytic Leukemia

Interventions: Drug: Daratumumab/rHuPH20
Drug: FT538
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2021-01-19

Last Posted Date: 2024-10-24

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 9

Registration Number: NCT04714372

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

FT516 and IL2 With Enoblituzumab for Ovarian Cancer

Phase 1

Completed

Conditions: Ovarian Cancer
Fallopian Tube Adenocarcinoma
Primary Peritoneal Cavity Cancer

Interventions: Drug: IP FT516
Drug: IL-2
Drug: Enoblituzumab

First Posted Date: 2020-11-16

Last Posted Date: 2023-04-03

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 3

Registration Number: NCT04630769

Locations: 🇺🇸
University of Minnesota, Masonic Cancer Center, Minneapolis, Minnesota, United States

A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma

Phase 2

Withdrawn

Conditions: Glioblastoma

Interventions: Drug: ONC201

First Posted Date: 2020-11-16

Last Posted Date: 2023-11-24

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Registration Number: NCT04629209

Locations: 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States

FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL

Phase 1

Completed

Conditions: NHL
Non Hodgkin Lymphoma
Diffuse Large B Cell Lymphoma
High-grade B-cell Lymphoma

Interventions: Drug: FT596
Drug: Rituximab

First Posted Date: 2020-09-21

Last Posted Date: 2024-07-09

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 7

Registration Number: NCT04555811

Locations: 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
Washington University School of Medicine - Siteman Cancer Center, Saint Louis, Missouri, United States

Diagnosis and Treatment of Periodontal Disease in Patients With AML

Not Applicable

Withdrawn

Conditions: AML
Acute Myelogenous Leukemia

Interventions: Other: Scaling and Root Planing

First Posted Date: 2020-08-28

Last Posted Date: 2023-02-22

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Registration Number: NCT04530695

Feasibility Study - Filter Ventilation

Not Applicable

Recruiting

Conditions: Tobacco Use

Interventions: Other: Unventilated filter cigarettes
Other: Ventilated filter cigarettes

First Posted Date: 2020-08-17

Last Posted Date: 2024-07-17

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 60

Registration Number: NCT04514471

Locations: 🇺🇸
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy